Samsung Biologics

207940.KO

696.91 USD

2.15

+0.31%

Overview

Last close

696.91 usd

Market cap

49.60B usd

52 week high

761.21 usd

52 week low

499.98 usd

Target price

697.84 usd

Valuation

P/E

N/A

Forward P/E

64.9351

Price/Sales

18.8682

Price/Book Value

7.7749

Enterprise Value

57.45B usd

EV/Revenue

18.864

EV/EBITDA

41.4253

Key financials

Revenue TTM

2.94B usd

Gross Profit TTM

1.47B usd

EBITDA TTM

1.32B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

12.15B usd

Net debt

N/A usd

About

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.